The familiar reliance on reading glasses for presbyopia, the age-related loss of near vision, may soon face significant competition from a new class of prescription eye drops. These innovative drops are designed to temporarily improve near vision, offering a glasses-free experience for several hours.
A Growing Market for Near Vision Correction
The development of these drops marks a notable shift in ophthalmology, with companies like Lupin spearheading their introduction into new markets. The US has provided early commercial success stories, demonstrating consumer interest in temporary near-vision correction.
Lupin, through its subsidiary VISUfarma, recently secured exclusive rights to commercialize Yuvezzi, developed by Tenpoint Therapeutics, across the European Union, UK, Switzerland, Norway, and Iceland. Yuvezzi received US FDA approval in January 2026 and became commercially available in the US in March 2026.
Yuvezzi functions by temporarily making it easier for the eye to focus on close objects. Clinical studies by Tenpoint showed improved near vision for up to eight hours, though the duration and degree of benefit can vary among individuals. It's important to note that these drops are not intended to permanently eliminate the need for reading glasses.
Commercial Traction and Strategic Acquisitions
The global presbyopia market was valued at an estimated $10.66 billion in 2025 and is projected to reach $13.88 billion by 2030, according to The Business Research Company. While this encompasses the broader market, prescription eye drops are carving out a significant niche.
Early commercial data from the US highlights this potential. LENZ Therapeutics reported $3.4 million in sales for its product, VIZZ, in the first half of 2026, with over 13,000 eye-care professionals prescribing it. Orasis Pharmaceuticals' Qlosi also showed a 49.1% refill rate 15 months post-launch, underscoring the demand for repeat purchases of these temporary vision solutions.
Lupin's move to acquire VISUfarma in April 2026 significantly bolstered its ophthalmology business, adding over 60 branded products and a strong commercial presence in key European countries. The subsequent addition of Yuvezzi further solidifies Lupin's strategy for specialty-led growth in the eye-care sector.
Coexistence, Not Replacement, Say Analysts
While promising, analysts suggest that prescription eye drops are unlikely to fully replace reading glasses. Salil Kallianpur, a pharma analyst, states,
“Prescription eye drops for presbyopia have the potential to create a meaningful new pharmaceutical category, but I don’t see them replacing reading glasses. The more likely outcome is coexistence where glasses remain the inexpensive, reliable default, while drops create a sizeable convenience market for patients who want several hours of spectacle-free near vision.”
The adoption of these drops will depend on their everyday value proposition: predictability, duration of effect, tolerability, affordability, and convenience. Unlike glasses, which are a one-time purchase, eye drops require daily administration. Consumers will weigh these factors against the cost and convenience of temporary relief.
In India, Entod Pharmaceuticals has also entered the market with PresVu, a pilocarpine hydrochloride formulation for adult presbyopia, indicating a global trend towards this new form of vision correction.